Bacteriophage Compositions for Antibiotic-Resistant NTM Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nontuberculous mycobacteria (NTM) infections are difficult to manage clinically due to antibiotic resistance and lack of effective treatment options, particularly in patients with cystic fibrosis.
Innovation Solution
Compositions comprising specific bacteriophages such as BPsΔ33HTH-HRM10, Muddy, ZoeJΔ45, and other bacteriophages are administered to treat NTM infections, targeting Mycobacterium species like Mycobacterium avium, Mycobacterium abscessus, and Mycobacterium smegmatis, including cystic fibrosis patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat NTM infections, then treatment is attempted, but the bacteria are resistant and treatment fails
Solution Approach 1:
The patent uses bacteriophages as intermediary agents to deliver therapeutic payloads (enzymes, toxins, or genetic material) directly into NTM bacteria. The phage acts as a mediator that overcomes antibiotic resistance by introducing new mechanisms of bacterial killing or metabolic disruption that are unrelated to conventional antibiotic pathways.
Solution Approach 2:
The invention modifies the parameters of bacterial vulnerability by introducing phage-encoded enzymes or proteins that alter bacterial cell wall synthesis, membrane permeability, or metabolic pathways. This changes the physiological state of the bacteria to make them susceptible to phage-mediated lysis or metabolic collapse, bypassing antibiotic resistance mechanisms.
2Adaptability or versatility
If new treatment approaches are developed for NTM infections, then therapeutic options increase, but treatment complexity increases
Solution Approach 1:
The patent segments the treatment approach by using different phage types (lytic, lysogenic, engineered phages) tailored to specific NTM species or clinical scenarios. Each phage is designed with specific functions (lysis, enzyme delivery, genetic modification) that can be selected based on the infection type, providing versatile treatment options without requiring a single complex multi-functional system.
3Reliability
If bacteriophage compositions are used to treat NTM infections, then bacterial reduction is achieved, but treatment specificity requirements increase
Solution Approach 1:
The patent employs universal phage platforms that can be adapted to target multiple NTM species. The phage compositions include broadly reactive phages or combinations of phages with overlapping host ranges, allowing a single treatment regimen to address diverse NTM infections while maintaining high specificity for mycobacterial targets through shared surface receptors or cell wall structures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bacteriophage compositions effectively reduce or eliminate NTM bacteria, providing therapeutic benefits by alleviating symptoms and improving pulmonary function in infected subjects.
Implementation Method 1
The bacteriophage compositions effectively reduce or eliminate NTM bacteria
Data Source
AI summary
Disclosed herein are compositions comprising bacteriophages and methods of using these compositions for treating NTM infections. The present disclosure also provides compositions for screening bacteriophages that are effective in treating NTM infections and methods of using the same.